Aclarion (Aclarion) Cash And Cash Equivalents : $2.13 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Aclarion Cash And Cash Equivalents?

Aclarion's quarterly cash and cash equivalents increased from Sep. 2023 ($0.16 Mil) to Dec. 2023 ($1.02 Mil) and increased from Dec. 2023 ($1.02 Mil) to Mar. 2024 ($2.13 Mil).

Aclarion's annual cash and cash equivalents increased from Dec. 2021 ($0.43 Mil) to Dec. 2022 ($1.47 Mil) but then declined from Dec. 2022 ($1.47 Mil) to Dec. 2023 ($1.02 Mil).

Aclarion Cash And Cash Equivalents Historical Data

The historical data trend for Aclarion's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Cash And Cash Equivalents Chart

Aclarion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.13

0.02

0.43

1.47

1.02

Aclarion Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial											0.45	0.61	0.16	1.02	2.13

Aclarion Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Aclarion (NAS:ACON) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Aclarion Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Aclarion's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021

Website

http://www.aclarion.com

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Executives

John Paul Lorbiecki	officer: Chief Financial Officer	238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness	director, officer: Chief Executive Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond	officer: Chief Strategy Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch	director	1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann	director	130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann	director, officer: Executive Chairman	8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks	10 percent owner	811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc	10 percent owner	7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc	10 percent owner	1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart	director	951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira	director	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal	director	C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404